Background and Objectives No evaluation of sex and race influences on mycophenolic acid (MPA) pharmacokinetics and adverse effects (AEs) during enteric-coated mycophenolate sodium (ECMPS) and tacrolimus immunosuppression are available. The primary objective of this study was to investigate the influence of sex and race on MPA and MPA glucuronide (MPAG) pharmacokinetics in stable renal transplant recipients receiving ECMPS and tacrolimus Methods The pharmacokinetics of MPA and MPAG and their associated gastrointestinal AEs were investigated in 67 stable renal transplant recipients: 22 African American males (AAMs), 13 African American females (AAFs), 16 Caucasian males (CMs), and 16 Caucasian females (CFs) receiving ECMPS and tacrolimus. A validated gastrointestinal AE rating included diarrhea, dyspepsia, vomiting, and acid-suppressive therapy was completed. Apparent clearance, clearance normalized to body mass index (BMI), area under the concentration-time curve from time zero to 12 h (AUC 12 ) and dose-normalized AUC 12 (AUC*) were determined using a statistical model that incorporated gastrointestinal AE and clinical covariates. Results Males had more rapid apparent MPA clearance (CMs 13.8 ± 6.27 L/h vs. AAMs 10.2 ± 3.73 L/h) than females (CFs 8.70 ± 3.33 L/h and AAFs 9.71 ± 3.94 L/h; p = 0.014) with a race-sex interaction (p = 0.043). Sex differences were observed in MPA clearance/BMI (p = 0.033) and AUC* (p = 0.033). MPA AUC 12 was greater than 60 mgÁh/L in 57 % of renal transplant recipients (RTR) with 71 % of patients demonstrating gastrointestinal AEs and a higher score noted in females. In all patients, females exhibited 1.40-fold increased gastrointestinal AE scores compared with males (p = 0.024). Race (p = 0.044) and sex (p = 0.005) differences were evident with greater MPAG AUC 12 in AAFs and CFs. Conclusion Sex and race differences were evident, with females having slower MPA clearance, higher MPAG AUC 12 , and more severe gastrointestinal AEs. These findings suggest sex and race should be considered during MPA immunosuppression. Clin Pharmacokinet (2015) 54:423-434 DOI 10.1007 Key Points This is the first report of sex and race differences in the pharmacokinetics of mycophenolic acid (MPA) and its glucuronide metabolite (MPAG) in stable African American (AA) and Caucasian renal transplant recipients receiving enteric-coated mycophenolate sodium (ECMPS) and tacrolimus as maintenance immunosuppression.
Introduction
Mycophenolic acid (MPA) is the active moiety in entericcoated mycophenolate sodium (ECMPS) and mycophenolate mofetil (MMF) [1] . Both MPA formulations are prescribed with tacrolimus or cyclosporine (ciclosporin) for maintenance immunosuppression [1] [2] [3] [4] . The ECMPS formulation provides similar efficacy to MMF and may have fewer gastrointestinal adverse effects (AEs) [1, 2, [5] [6] [7] [8] . MPA-associated gastrointestinal AEs may reduce medication adherence, patient tolerability, and therapeutic MPA exposure, resulting in decreased allograft survival [2, 7, [9] [10] [11] .
MPA has complex metabolism and notable inter-and intra-patient pharmacokinetic variability, which is related to the inactive metabolite, MPA glucuronide (MPAG) [1, [12] [13] [14] . Clinical and demographic factors contribute to inter-patient variability in MPA and MPAG pharmacokinetics and include renal function, race, sex, albumin, hemoglobin, hematocrit, age, calcineurin inhibitor therapy, and time post-transplant [1, 15, 16] . Prior research has described race differences in MPA and MPAG pharmacokinetics with MMF or ECMPS in African American (AA) and Caucasian renal transplant recipients receiving cyclosporine, with a suggested sex influence [16, 17] . These studies were unique due to inclusion of intensive pharmacokinetic sampling with statistical models including pertinent clinical covariates to assess variability. These data contrast with other MPA pharmacokinetics in recipients receiving cyclosporine where no race or sex differences were found [18, 19] . To emphasize the need for evaluation of patient sub-populations, the US Food and Drug Administration has advocated for pharmacokinetic assessments of new formulations of approved medication that include race and sex studies [20] [21] [22] [23] . This approach may prevent clinicians from assuming that different formulations yield similar pharmacologic profiles in patient sub-populations.
MPA and MPAG pharmacokinetics and immunosuppression in renal transplant recipients are affected by the choice of the calcineurin inhibitor in the regimen [1, [24] [25] [26] . More enterohepatic circulation of MPAG occurs with concurrent tacrolimus, with increased amount of the active moiety, MPA, through intestinal and hepatic transport via the multi-drug resistance protein 2 (MRP2) resulting in an increased MPA area under the concentration-time curve (AUC) [24] [25] [26] [27] . In contrast, MPA exposure is reduced by cyclosporine due to inhibition of MRP2 function possibly contributing to less enterohepatic circulation [24] . The influence of race and sex on this complex calcineurin inhibitor interaction with MRP2 has not been assessed. Since MPA and tacrolimus regimens are the most common immunosuppressive therapy prescribed in the USA, studies of this combination in AA and Caucasian male and female recipients are warranted and timely [28] .
The primary objective of this study was to investigate the influence of sex and race on MPA and MPAG pharmacokinetics in stable renal transplant recipients receiving ECMPS and tacrolimus immunosuppression using a statistical model incorporating pertinent clinical factors with enterohepatic circulation. The secondary objective was to evaluate MPA-associated gastrointestinal AEs using a validated, standardized assessment scale and the association with race, sex, and MPA pharmacokinetics [29] .
Methods

Study Population
Sixty-seven (35 AA and 32 Caucasian) stable male and female renal transplant recipients receiving maintenance immunosuppression of tacrolimus (Prograf Ò , Astellas Pharma, Inc., Northbrook, IL, USA) and MPA as ECMPS (Myfortic Ò , Novartis, East Hanover, NJ, USA) for at least 6 months were evaluated in a 12-h pharmacology study. Patients were considered clinically stable by physical examination, comprehensive metabolic panel, and complete blood count at enrollment and prior to the study.
Tacrolimus doses were adjusted to target troughs from 3 to 7 ng/mL based upon time post-transplant and clinical response. MPA dosing adjustment was based upon clinical response and AEs without therapeutic drug monitoring. Medication adherence at enrollment and 1 week prior to the study was documented. Ethnicity for two previous generations was verified.
The inclusion criteria were as follows: (1) C6 months post-renal transplant; (2) age 25-70 years; (3) first or second time deceased-donor or living allograft recipient; (4) stabilized on same dose of immunosuppressive drugs for C7 days prior to study; (5) serum creatinine B3.25 mg/ dL with no change in serum creatinine[0.25 mg/dL during prior two visits; and (6) leukocyte count C3,000/mm 3 and hemoglobin C8.0 g/dL. Exclusion criteria were as follows: (1) significant gastrointestinal disease; (2) infection within 2 weeks prior to study; (3) acute rejection within 2 weeks of study; (4) drugs interfering with MPA absorption; and (5) significant cardiovascular, hematologic, psychiatric, neurologic, or oncologic disease that would limit participation.
Study Procedure
This was a cross-sectional, open-label pharmacokinetic study in stable male and female AA and Caucasian renal transplant recipients receiving chronic immunosuppression of tacrolimus (Prograf Ò ) and MPA as ECMPS (Myfortic Ò ) for at least 6 months. A sample size of at least 13 stable transplant patients for each race-gender group addressed the primary study objective.
This study was conducted at the University at Buffalo (UB) Renal Research Center at the Erie County Medical Center (Buffalo, NY, USA). Prior to study initiation, the UB Health Sciences Institutional Review Board approved the study (IRB# PHP0720608B), which was conducted in accordance with the Declaration of Helsinki. Upon enrollment, patients provided written consent after review of the study purpose, risks, and benefits.
All patients were studied at steady-state conditions of ECMPS and tacrolimus with receipt of the same dose of immunosuppressive drugs for at least 7 days prior to study. Proton pump inhibitors, histamine H 2 antagonists, and antacids were discontinued at least 36 h preceding study. Patients remained in an upright position throughout the study. Standardized low-fat and -sodium meals were provided after the first 4 h and consistently timed for study duration. Anti-hypertensive drugs were administered after 1.5 h, while insulin, anti-lipidemic, and other medications were administered 4 h after the immunosuppressives. Blood samples (7 mL) were collected and placed on ice at 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, and 12 h after drug administration. Plasma samples were harvested within 1 h and stored at -70°C until analysis. Clinical laboratory tests and tacrolimus troughs were analyzed in the Clinical Laboratory at the Erie County Medical Center.
Gastrointestinal Adverse Effect (AE) Evaluation
Common drug-related gastrointestinal AEs (Table 1) were evaluated by trained nephrologists during the 12-h study using validated criteria with assignment of severity (i.e., 0 = no AE; 1? = mild to 3? = severe manifestations) [29] . Significant gastrointestinal disease was excluded prior to patient enrollment. Patients received a ranked score for each gastrointestinal AE during the physical examination. A gastrointestinal score was then determined as the sum of the rating for each individual AE to compare severity with a possible minimum score of zero and maximum score of 9. Due to limited sample size, each gastrointestinal AE was reported dichotomized as present or absent and monitored from enrollment through study.
Assay Methodology
A liquid chromatography/mass spectrometry assay was used for the simultaneous analysis of plasma MPA and MPAG with 5,5-diphenylhydantoin and flumethasone as internal standards, respectively [30] . Standard curve concentrations ranged from 0.145 to 15.5 lg/mL for MPA and from 22.1 to 295.2 lg/mL for MPAG. The lowest limit of quantitation was 0.072 lg/mL for MPA and 11.1 lg/mL for MPAG. The relative standard deviation for intra-day variation for MPA ranged from 1.6 to 2.7 % and 2.87 to 6.54 % for MPAG. The relative standard deviation of interday variation for MPA ranged from 2.3 to 4.5 % and 3.8 to 7.5 % for MPAG. Tacrolimus troughs were analyzed within 24 h at ECMC Clinical Laboratory using the ARCHITECT Ò Tacrolimus assay (Abbott, Abbott Park, IL, USA), a chemiluminescent microparticle immunoassay. The lower limit of detection was 1.5 ng/mL and intra-day assay variability was less than 7 %.
Pharmacokinetic Analysis
Pharmacokinetic parameters for MPA and MPAG included the AUC from time zero to 12 h (AUC 12 ), MPA dosenormalized AUC 12 (AUC*), 12 h trough (C 12 ) and maximum (peak) concentrations (C max ), and time to C max (t max ). The dose-equivalent MPA was utilized. Oral apparent clearance of MPA was calculated as the ratio of MPA dose equivalent to MPA AUC 12 . MPA clearances were adjusted for body mass index (BMI) to assess the impact of standardized body weights. Clearance and AUC 12 were determined by the linear trapezoidal rule using noncompartmental pharmacokinetic methods (Phoenix WinNonlin Ò version 6.3. Pharsight Corp., Mountain View, CA, USA). Since patients were stabilized on different daily doses of MPA, MPA AUC 12 was dose normalized to 1 mg MPA dose equivalent due to drug linearity to generate AUC* [1, 31] .
Patients were identified as having enterohepatic circulation using the following criteria: (a) inspection of the MPA concentration-time profiles for appearance of a second peak occurring from 6 to 12 h over the dosing interval; and (b) an increase in MPA concentration greater than 25 % compared with the previous timepoint during the elimination phase [16, 17, 32 ].
Statistical Analysis
The sample size was determined based upon a power of 80 % to detect a difference of 30 % in the MPA oral clearance between AA and Caucasian male and female recipients with a coefficient of variation of 30 %. This required at least 13 patients per race-sex group.
Descriptive statistics such as frequencies and relative frequencies were computed for all categorical variables. Numeric variables were summarized using simple descriptive statistics including means and standard deviations with graphical techniques utilized for displaying data. ANOVA was used to compare groups defined by race and sex in the case of continuous parameters such as pharmacokinetic endpoints, demographics, and clinical factors. A secondary analysis was completed to evaluate the presence or absence of enterohepatic circulation as a binary dependent variable in relation to the groups using logistic regression. Enterohepatic circulation was used as a covariate in relation to MPA and MPAG pharmacokinetics and gastrointestinal AE score between groups. Pair-wise comparisons utilized TukeyKramer correction for multiple testing. Diagnostic plots were used to assess model fit and identify the need for data transformations. All data were found to meet model assumptions and no data required transformation. The modeling of binary endpoints for AEs was performed in a similar fashion using logistic regression techniques. Statistical outliers were defined as studentized residuals outside ±3. Our results had no outliers. In the case of gastrointestinal AE endpoints, groups were compared using the Wilcoxon test.
To further examine race-sex group differences in MPA and MPAG pharmacokinetics, in the presence of important patient factors including age, tacrolimus trough, estimated glomerular filtration rate (eGFR) [33] , albumin, hemoglobin, hematocrit, time post-transplant, presence of diabetes, and enterohepatic circulation were included in the established linear statistical model and refit using each covariate (factor) as an independent variable in a separate model [1] . The partial coefficient of determination for each pair of dependent and independent variables was calculated to estimate the variability explained by the independent variable relative to the grouping variables. All tests were twosided with nominal significance level of 0.05 utilized for all hypotheses testing with SAS Ò statistical software (version 9.3, SAS Institute, Cary, NC, USA).
Results
Patients
Sixty-seven renal transplant recipients [13 AA females (AAFs), 16 Caucasian females (CFs), 22 AA males This table provides the validated standardized rating scale utilized by clinicians for assessment of gastrointestinal adverse effects in each renal transplant recipient. For each patient, the score for each adverse effect that quantitates the severity was used to generate a total gastrointestinal adverse effect score [29] (AAMs), and 16 Caucasian males (CM)] completed this study with no differences in ages and times post-transplant. Demographics and clinical characteristics are summarized in Table 2 . Albumin, liver function tests, and hematologic parameters were within the normal range for all patients. Females had lower albumin, hemoglobin, eGFR, and total and lean body weights. No differences in BMI were found among groups. AAs had higher serum creatinine values as expected. Mean tacrolimus trough concentrations and MPA doses were similar among groups. Diabetes was present in 52 % of AAs and 48 % of Caucasians. No data transformation was required for demographics or pharmacokinetic results. 12 patterns were observed among these four race-sex groups (Fig. 2a-d) . One concentration-time pattern was bimodal with an initial increase in MPA concentrations representing drug absorption followed by a second increase from 6 to 12 h. This pattern has been attributed to enterohepatic circulation of MPAG to MPA [1] . Enterohepatic circulation was found in 86.4 % of AAMs; 81.3 % of CMs; 61.5 % of AAFs; 75.0 % of CFs [33] (p = 0.400). Although no sex or race differences were found for total MPA AUC 12 , drug exposure comparisons are depicted in Fig. 3 using the MPA AUC 12 therapeutic range of 30-60 mgÁh/L established for steady-state MMF and cyclosporine regimens [14, 34] . Six patients (\9 %) (three Caucasians; three AAs) had an MPA AUC 12 less than 30 mgÁh/L, 23 (34 %) patients had an AUC 12 between 30 and 60 mgÁh/L (ten AAs; 13 Caucasians), and 38 patients (57 %) (22 AA; 16 Caucasians) had an AUC 12 greater than 60 mgÁh/L with empiric dosing [22, 34] (see Fig. 3 ). Fifty percent of patients with an MPA AUC 12 [60 mgÁh/L were females (ten AAs; nine Caucasians). Sex differences were found with MPA AUC* (p = 0.033) with the lowest AUC* found in CMs.
Pharmacokinetics
Sex and race influences were exhibited with MPAG pharmacokinetics (Table 3 ). Sex differences in MPAG C 12 (p = 0.014) and C max (p = 0.017) were observed with the greatest exposures observed in AAFs. For MPAG AUC 12 , sex (p = 0.005) and race (p = 0.044) differences were found, with AAFs exhibiting almost twice the metabolite exposure as CMs. Sex (p = 0.031) difference with a racial trend (p = 0.053) were noted in the ratio of MPAG AUC 12 to MPA AUC 12 (metabolite to active drug exposure) when adjusted for hemoglobin with AAFs exhibiting the highest ratio.
Analyses pertaining to MPA and MPAG pharmacokinetic variability provided insight into the effect of clinical covariates and included renal function (eGFR), hemoglobin, and tacrolimus troughs. Inverse associations between the eGFR and MPA C 12 (p = 0.009), AUC 12 
Gastrointestinal AE Evaluation
The gastrointestinal AEs were assessed using standardized criteria by trained nephrologists and are summarized in Table 4 using the criteria given in Table 1 . Sex differences were present in the gastrointestinal AE score (p = 0.024) after adjustment for renal function, and AAFs exhibited the highest score (3.23 ± 1.42). For patients with MPA AUC 12 [60 mgÁh/L (Fig. 3) 12 [60 mgÁh/L, 97 % (37/38) had an MPA trough greater than 1.9 mg/L as established for MMF and tacrolimus [14] . For all 67 patients, recipients with enterohepatic circulation had a lower gastrointestinal AE score (2.23 ± 1.69) than the no recycling group (3.40 ± 1.81; p = 0.027). No difference was found in the MPAG AUC 12 /MPA AUC 12 in patients with enterohepatic circulation (13.61 ± 6.00) compared with no recycling (15.64 ± 6.48; p = 0.25). No significant associations of gastrointestinal score with MPA or MPAG AUC 12 or C 12 for the entire group were found. No group differences were found for individual gastrointestinal symptoms dichotomized as present or absent.
Discussion
Demographics, clinical factors, and concurrent medications influence inter-patient variability in MPA and MPAG 
pharmacokinetics but are rarely evaluated in bioequivalence studies of new formulations [1, 20, 35] . Since the combination of MPA and tacrolimus is the most frequently prescribed immunosuppressive regimen in the USA, we examined race and sex influences on the MPA and MPAG pharmacokinetics of the ECMPS formulation using an intensive sampling approach [28] . Sex influences were observed with more rapid apparent MPA clearance and clearance/BMI, and lower MPA AUC* in CMs than in AA and Caucasian females. A sex and race association was described with MPAG AUC 12 , with renal function (eGFR) identified as a covariate accounting for variability . Interestingly, a sex effect was also detected in the gastrointestinal AE score, with the highest score in AAFs. MPA is extensively bound to albumin and competes with MPAG for binding [1, 36] . With a decline in renal function, accumulation of urea and other uremic compounds compete for albumin binding sites with the concurrent reduction in renal clearance of MPA and MPAG [1, 37] . These pharmacokinetic changes lead to an increased unbound drug concentration, and when accompanied by reduced renal function in female patients may partially account for sex differences in MPA and MPAG [1] . However, no clinical MPA AUC 12 guidelines have been developed that would individualize ECMPS or MMF dosing according to patient subpopulations and declining renal function [14] .
In addition to a sex effect, a combined sex-race influence was observed with a more rapid MPA clearance in CMs than in CFs and similar findings in AA females and males. A sex effect and racial trend were found in the MPAG AUC 12 /MPA AUC 12 with the lowest ratio found in CMs, suggesting more extensive deconjugation of the metabolite MPAG by uridine diphosphate glucorosyltransferase (UGT) to MPA in males. Sex differences in glucuronidation, with males exhibiting a more rapid clearance, have been reported; however, generally, race influences remain to be investigated for most medications [38] [39] [40] . During a study that used therapeutic drug monitoring, MPAG/MPA trough ratios were higher in male renal transplant recipients than females, suggesting sex differences in glucuronidation [40] . However, MPA clearance was not determined and the use of the trough plasma ratio may be influenced by renal allograft function and concurrent cyclosporine therapy. Therefore, studies that are limited to trough concentration comparisons require further investigation utilizing a study design that employs pharmacokinetic analysis with intensive sampling. Population pharmacokinetic studies have described sex influences on MPA and MPAG as confirmed in our current study [41, 42] .
The calcineurin inhibitor combined with MPA may further contribute to inter-patient variability in MPA and MPAG pharmacokinetics and the resulting differences in systemic drug exposure [43] [44] [45] . The MRP2 efflux transporter in liver, kidney, and gut epithelium apical cell membranes plays a central role in the enterohepatic circulation of MPAG [46] . MPAG is then converted to MPA through deconjugation and is detected as a second peak in the pharmacokinetic profile that is observed beyond 4 h after drug administration [24, 47, 48] . Cyclosporine inhibits MRP2, thus preventing enterohepatic circulation of MPAG and minimizing its contribution on MPA pharmacokinetics [24, 47] . However, tacrolimus does not interfere with MRP2 and enterohepatic circulation of MPAG is present, contributing to an increased MPA exposure as measured by a greater AUC 12 , slower MPA clearance, and reduced MPAG AUC 12 compared with cyclosporine [43, 47, 48] . Enterohepatic circulation is rarely described in MPA and MPAG pharmacokinetic studies but remains an integral component to accurate drug exposure [4, 49] Our group has described a disparity in enterohepatic circulation present in Caucasian and AA male recipients stabilized on either MMF or ECMPS with cyclosporine [17] . The incidence of enterohepatic circulation may also be influenced by a range of cyclosporine concentrations among patients in these reports [24] . The minimization of calcineurin inhibitors post-transplantation is likely to result in a range of drug exposures that lead to inter-individual differences in MRP2 function and the presence or absence of enterohepatic circulation. Dosing adjustments to the immunosuppressive regimen may also be a factor that contributes to MPA pharmacokinetic variability and requires further evaluation in patient subpopulations [50] . Therefore, clinicians should consider monitoring MPA and MPAG concentrations in patients during cyclosporine or tacrolimus dose adjustments or switching between MPA formulations due to the resulting change in enterohepatic circulation that impacts MPA and MPAG pharmacokinetics and immunosuppression. An interesting observation was that 57 % of our subjects had an MPA AUC 12 [60 mgÁh/L (Fig. 3) , a value that is considered to be above the upper end of the therapeutic range for MMF and cyclosporine immunosuppression [14] . In spite of using an empiric dosing approach, less than 9 % of these patients had MPA AUC 12 less than 30 mgÁh/L. Conflicting results from large clinical trials have been reported comparing fixed dosing with concentration-controlled approaches using the predicted MPA AUC 12 for dose adjustment of MMF regimens administered with cyclosporine or tacrolimus [51] [52] [53] . These studies have provided guidance for development of MPA therapeutic ranges for ECMPS in tacrolimus-based immunosuppression in spite of the differing MMF pharmacokinetics [51] [52] [53] .
The higher gastrointestinal AE score in AAFs provides the first sex-specific observation of MPA-associated AEs. The occurrence of gastrointestinal AEs may reduce medication adherence and quality of life, with a potential influence on the maintenance of long-term therapeutic MPA exposure and healthcare costs associated with allograft complications [8-10, 12, 54] . The proposed mechanism(s) that lead to gastrointestinal AEs include gut epithelial UGT that produces MPAG, enterocyte villous atrophy with MPA effects, and enterocyte inosine monophosphate dehydrogenase [55] . Reducing gastrointestinal AEs associated with MPA is important for overall allograft survival and patient quality of life [9, 55] . Although it is unclear if there are fewer gastrointestinal AEs associated with ECMPS than with MMF, it has been suggested that patient tolerance is improved with this enteric-coated formulation [2, 54, 55] . The gastrointestinal AE assessment scale we utilized was a component of the comprehensive immunosuppressive AE assessment developed to compare inter-and intra-patient AE severity [29] . Interestingly, patients with enterohepatic circulation had a lower gastrointestinal AE score than recipients with no recycling and requires further investigation. The gastrointestinal AE score was not associated with MPA or MPAG pharmacokinetics, possibly a reflection of the sample size. However, these findings are consistent with sex-specific observations for adverse drug effects in the general population [56, 57] .
A limitation of our study is that we evaluated stable patients using a cross-sectional, observational design. Therefore, our findings should be verified in a prospective manner to confirm the sex association with AEs we identified.
Conclusion
This study is the first to report sex and race differences in MPA and MPAG pharmacokinetics and gastrointestinal AEs in stable renal transplant recipients receiving ECMPS and tacrolimus. These differences may occur through modification of MRP2 function, sex-related differences in deconjugation of MPAG to MPA, and altered protein binding to albumin of MPA and MPAG during renal dysfunction. Our findings may have important clinical implications for ECMPS dose adjustments between sex and race, during dose adjustment of tacrolimus and between MPA formulations, and the potential use of therapeutic drug monitoring.
